Login to Your Account

Actelion Must Pay $547M in Dispute with Asahi Kasei

By Nuala Moran

Wednesday, May 4, 2011
LONDON – The pressure on Actelion Ltd. is intensifying after a U.S. jury said the company should pay out $547 million in its license dispute with Asahi Kasei Pharma Corp of Tokyo.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription